Tags Archive Navigation
icon
-
StorySolving the puzzle of immunotherapy
-
Media ReleaseFDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
-
Featured NewsSound Up for Lung Cancer
-
StoryDemystifying the science of myelodysplastic syndromes
-
Media ReleaseNovartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer
-
Media ReleaseSandoz announces EU launch of ready-to-dilute generic Pemetrexed to treat most prevalent form of lung cancer
-
Media ReleaseNovartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma
-
Media ReleaseNovartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other key data at ESMO
-
Media ReleaseNovartis announces first FDA filing acceptance for anti-PD-1 antibody tislelizumab for people with esophageal cancer
-
Media ReleaseSandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine
-
Media ReleaseNovartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
-
Media ReleaseNovartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021
Pagination
- ‹ Previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- …
- 14
- › Next page